

August 2021

Notification of Global Shortage of Actemra IV (tocilizumab)

The unprecedented surge in worldwide demand and supply constraints driven by the COVID-19 Delta variant has led to a temporary global shortage of Actemra IV (tocilizumab). See below for the impacted NDCs, current as of August 20, 2021.

Description	NDC	Status
ACTEMRA IV 400mg/20mL Vial	50242-0137-01	Stockout
ACTEMRA IV 200mg/10mL Vial	50242-0136-01	Stockout
ACTEMRA IV 80mg/4mL Vial	50242-0135-01	Stockout
ACTEMRA Subcutaneous (ACTPen®) 162mg/0.9mL Autoinjector	50242-0143-01	Available (On Allocation)
ACTEMRA Subcutaneous 162mg/0.9mL Prefilled Syringe	50242-0138-01	Available

Genentech expects the scheduled replenishments to arrive by the end of August and at intervals through the end of 2021. However, if the pandemic continues to spread at its current pace, we anticipate additional periods of stockout in the weeks and months ahead, at least through the end of the year.

Currently, we have a limited supply of subcutaneous Actemra available for approved indications, though the supply situation continues to evolve. (Subcutaneous Actemra is not authorized for the treatment of COVID-19 patients under the Emergency Use Authorization.) To minimize disruption to patient care and address the current imbalance between supply and increasing demand, authorized distributors will be allocating the Actemra Subcutaneous Autoinjector and any new supply of Actemra IV for all customers until supply can meet demand. 340B entities will be subject to the same allocation as all other purchasers.

Genentech regrets any hardship these changes may cause. The US and global impact of COVID-19 is rapidly evolving in unexpected ways, so Genentech asks for your continued engagement and understanding during this pandemic to serve the greatest number of patients possible together, and as supply permits.

For questions regarding fulfillment of Actemra IV order requests, hospitals and practices should contact their Distributor. More information can be found on this [site](https://www.gene.com/contact-us/customer-service/product-distribution/purchasing-actemra):
<https://www.gene.com/contact-us/customer-service/product-distribution/purchasing-actemra>.

For more information on the global Actemra supply situation, please see the Roche media statement [here](#).